Latham & Watkins Advises the Underwriters in the offering while Cooley LLP represented Lyell Immunopharma. Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming company...
Lyell Immunopharma’s $425 Million Initial Pubic Offering
UiPath’s $1.54 Billion Initial Public Offering
Davis Polk advised the representatives of the several underwriters on the deal while Cooley LLP represented UiPath. UiPath, Inc. executed its $1.54 billion initial public offering of...